Antinol® Latest Studies
Sorted by recent
Filter Studies by Smart Tags
Bone & JointCardiovascularCase Study & ProceedingCatDogEAB 277™EfficacyExotic PetImmunologyNeuro & BehaviorOphthalmologyOralRabbitRenalRespiratoryRodentSafetySkinUTI
Smart Search
Use of PCSO-524®(Antinol®) in a Pomeranian Dog with Degenerative Mitral Valve Disease (DMVD) and Cardiac Tumor of the Left Atrium
Authors:
A 10-year old Pomeranian dog with degenerative mitral valve disease (DMVD) and cardiac tumor of the left atrium was treated with pimobendan, ramipril, and furosemide in conjunction with PCSO-524® (Antinol®) as supplemental therapy.
After the treatment, the dog showed improved ability to conduct various activities, increased appetite and ingestion, weight gain and disappearance of paroxysmal ventricular premature contraction (VPC).
The C-reactive protein (CRP), which is an inflammatory marker in dogs, also decreased to normal level within 21 days of PCSO-524® (Antinol®) supplementation.
Use of PCSO-524® for Supplementary Treatment of Protein Losing Nephropathy in Animals
Authors:
An intact male Shih Tzu dog weighed 5.8 kilograms was referred to Suvarnachad Animal Hospital with signs of polydipsia, polyuria, edema and ascites due to accumulation of fluid in the abdominal cavity.
Biochemical tests found hypoalbuminemia, hyperglobulinemia, hypercholesterolemia, increased urine protein creatinine ratio (UPC) to 5.88 and no signs of inflammation or infection of the urinary tract.
Protein losing nephropathy from glomerular disease was diagnosed based on the biochemical indicators. Medication was given to the dog in order to control kidney damage and minimize the clinical symptoms.
Anti-proteinuric drug, for example ACE inhibitor to reduce blood pressure, was particularly selected for the treatment in conjunction with prednisolone and PCSO-524® as supplementary treatment.
During the 10 months follow up, the dog showed improvement of clinical symptoms, no edema, lack of accumulation of fluid in abdomen cavity, and serum albumin that was increased to normal level.
Use of PCSO-524® and Cyclosporin for Treatment of Immune-Mediated Polyarthritis in Dogs
Authors:
An 8 years old Chihuahua dog was admitted to the Small Animal Hospital at Chulalongkorn University due to signs of depression, lethargy, lameness and joint effusion. Hematological examination and test of synovial fluid indicated Immune-Mediated Polyarthritis (IMPA).
Prednisolone, Gabapentin and Amoxillin-clavulanic acid were prescribed for the treatment. Abnormally increase of ALT, ALK and AST enzyme was observed 1 week later, therefore, the treatment was changed to Cyclosporin, Gabapetin, and PCSO-524®. The clinical signs continued to improve after the adjustment of prescription and Cyclosporin and Gabapetin were terminated after 3 and 4 months, respectively.
A follow-up examination at 4 months later showed no signs of lameness and joint effusion and no adverse effects caused by the long-term use of PCSO-524®.
The success of IMPA treatment is a result of rapid diagnosis and appropriate treatment protocol. Follow-up for treatment evaluation is necessary during the treatment course in order to reduce the impact on health and minimize the medication dosage without risk of causing adverse effects or recurrence of the disease.
PCSO-524® for Treatment of Immune-Mediated Polyarthritis in Dogs
Authors:
An 8-year old Chihuahua dog was admitted for surgical treatment of patella luxation at Small Animal Hospital of Chulalongkorn University, Thailand.
At 2 weeks prior to the hospital visit, the dog showed signs of fever, anorexia, lethargy, and lameness of the left leg. Non-steroidal anti-inflammatory drug (NSAIDs) was prescribed at that time but the dog had no response to the treatment.
The dog received prednisolone 0.6 mg/kg bid, gabapentin 10 mg/kg sid, samylin® liver supplement 1 tablet sid, and amoxicillin-clavulanic acid 20 mg/kg sid in the first week of the treatment. Then prednisolone was stopped due to elevation of liver enzymes; AST, ALT, and ALK.
The following 1-month treatment course included cyclosporine 6 mg/kg bid, gabapentin 10 mg/kg bid, samylin® 1 tablet sid, and PCSO-524® 1 capsule bid.
This article was summarized from the original article published in The Journal of Thai Veterinary Practitioners by the permission of Veterinary Practitioner Association of Thailand (VPAT)
Report Clinical Results of Feline Patients with Chronic Kidney Disease (CKD) that received PCSO-524® Vol.10 (2019 February)
Authors:
Chronic Kidney Disease in cat(2) treated with Antinol®
Mongrel Cat, 7 years old was admitted to Maizuru Animal Medical Center, Kidney disease was observed.
Overview: Patient was repeatedly hospitalised for treatment of CKD. But two weeks after Antinol® was added to treatment regimen, decrease in BUN, Are, and P level as well as improvement of appetite and activity was observed.
(Addition of Antinol® to treatment: 1st 2 weeks; 2 caps / day, orally. Continued with 1 caps / day, orally for 1 week. Increased dose in the 4th week to 2 caps / day, orally since appetite decreased.)
Antinol® Case Study Contest 2018
The 6 Case Studies from Antinol® Case Study Contest of 2018.
Antinol® Contest has been organized successfully for 3 years since 2016 in Thailand.
The key objective of this scientific contest is to encourage knowledges sharing amongst the Vet practitioners on how to treat the companion animals inflammatory cases safely & effectively by using Antinol in conjunctive with others medicines especially the NSAIDs (Non Steroidal anti-inflammation drugs) which is the drug of choices of anti-inflammatory problems.
Report Clinical Results of Feline Patients with Chronic Kidney Disease (CKD) that received PCSO-524® Vol.9 (2018 September)
Authors:
Chronic Kidney Disease in cat(1) treated with Antinol®
Mongrel Cat, 7 years old was admitted to Maizuru Animal Medical Center, patient was diagnosed with CKD
Overview: Patient was not responding to treatment but decrease in BUN and Creatinine (Are) levels were observed after Antinol® was added to treatment regimen.
(Addition of Antinol® to treatment: 1st 2 weeks; 2 caps / day orally. Continued with 1 caps / day orally.)
PCSO-524® (Antinol®) Use in Persian Cat with Dynamic Hypertrophic Obstructive Cardiomyopathy (HOCM)
Authors:
A Persian cat aged 21 years was diagnosed with Dynamic Hypertrophic Obstructive Cardiomyopathy (HOCM) and treated with PCSO-524® (Antinol®) for 45 days.
The cat regained quality of life and daily activities such as grooming and walking, increased appetite, ingestion and weight gain after the treatment. Serum Amyloid A (SAA), which is an inflammatory marker in cats, was reduced down to normal after 15 days of PCSO-524® (Antinol®) administration.
Use of PCSO-524® (Antinol®) and Antipruritic Drug for Treatment of Itch Caused by Flea Allergy Dermatitis (FAD) and Psychological Alopecia in Domestic Short Hair Cat
Authors:
The cat in this case was affected with skin disease caused by flea allergy dermatitis (FAD) and psychological alopecia.
Holistic treatment was the choice of treatment in this case. Medical treatment was applied to the cat and environments surrounding the cat was managed. PCSO-524® (Antinol®) in combination with other antipruritic drugs was used to relieve itch and inflammation of the chronic skin disease and to strengthen the skin.
During 210 days of the study, environment was managed and intensive parasitic control was applied to every cat in the house in order to control flea. The study showed efficacy of PCSO-524® (Antinol®) for treatment of skin inflammation, strengthening the skin, and itch relief.
During day 160-210 of the treatment, administration of other anti-itch drugs was terminated due to psychological alopecia that caused constant licking by the cat. PCSO-524® (Antinol®) was recommended in this case since it can be used for long-term treatment without adverse effects.
The study concluded that PCSO-524® (Antinol®) in combination with other antipruritic drugs and environmental management is effective.
Updated Study Topics
New researches and publications related to PCSO-524® and its result in clnical test submitted by veterinarians on the global conferences every year and the data keeps growing with more studies conducted
